WEHI Blood Cells and Blood Cancer Special Seminar hosted by Professor Andreas Strasser

Masha Poyurovsky, PhD

Vice President, Biology – PMVPharma, USA

Discovery and Functional Characterization of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Clinical Development

 

Davis Auditorium

Join via TEAMS

Including Q&A session

Please note this presentation will not be recorded

Masha Poyurovsky, PhD is Vice President and Head of Biology at PMV Pharmaceuticals, where she leads discovery biology, in vivo pharmacology, and translational research across multiple oncology programs from target validation to Phase 1 clinical development, with a particular focus on mutant-selective cancer therapeutics. Dr. Poyurovsky has been instrumental in advancing PMV’s first-in-class mutant p53 reactivation program, rezatapopt. Her work bridges deep mechanistic insight into p53 biology with modern precision-oncology approaches. Dr. Poyurovsky is the author of numerous publications and patents in cancer biology and drug discovery and is recognized for translating fundamental cancer biology into therapeutic strategies.

Prior to PMV, Dr. Poyurovsky spent over a decade at Kadmon Pharmaceuticals (now Sanofi), where she served as Vice President of Discovery Biology and helped advance multiple small-molecule and biologics programs from early discovery into the clinic. Her earlier academic career at Columbia University focused on the molecular regulation of p53, MDM2, and cancer metabolism. 

All welcome!